Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 334, Issue 1-2, Pages 123-125Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2013.08.007
Keywords
Inclusion body myositis; IL1 receptor anakinra; Autoimmunity; Inflammatory cytokines; Cyrotoxic T-cells
Categories
Ask authors/readers for more resources
In sIBM, an inflammatory process mediated by cytotoxic T cells and cytokines in conjunction with a degenerative process, deposits of beta amyloid and misfolded proteins appear to be the main culprits in disease pathogenesis. IL-1 beta may play a key role because it is upregulated in sIBM myofibers, co-localizes with Amyloid Precursor Protein (APP) and promotes the production of APP and amyloid deposits. We performed a small, pilot study to examine whether anakinra, an IL1 receptor antagonist could benefit slBM patients. Four patients with biopsy-proven sIBM received anakinra for a mean period of 7.7 months. No improvement in muscle strength or stabilization was noted in any of the patients based on grip strength and MRC measurements. The treatment failure may be due to insufficiency of anakinra to suppress the intramuscular IL1 the short study period, or the irrelevance of IL1 in the disease process. 2013 Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available